PPA
RDHL

Parametric Portfolio Associates’s Redhill Biopharma RDHL Stock Holding History

Parametric Portfolio Associates’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-43
Closed -$110K – 3751
2021
Q4 		$110K Sell
43
-6
-12% -$24K ﹤0.01% 3539
2021
Q3 		$222K Buy
49
+3
+7% +$20.4K ﹤0.01% 3398
2021
Q2 		$315K Buy
46
+3
+7% +$20.7K ﹤0.01% 3256
2021
Q1 		$315K Buy
43
+9
+26% +$75.5K ﹤0.01% 3697
2020
Q4 		$277K Buy
34
+1
+3% +$8.99K ﹤0.01% 3634
2020
Q3 		$338K Buy
33
+5
+18% +$41K ﹤0.01% 3437
2020
Q2 		$186K Buy
28
+3
+12% +$20.7K ﹤0.01% 3647
2020
Q1 		$113K Buy
25
+14
+127% +$70K ﹤0.01% 3704
2019
Q4 		$68K Buy
+11
New +$70.3K ﹤0.01% 3905

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Parametric Portfolio Associates's RDHL Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Redhill Biopharma (RDHL) in Q1 2022, closing a stake of 43 shares — an estimated $110K sold.

Parametric Portfolio Associates first reported a position in RDHL in Q4 2019 and held it in 9 quarters. The position peaked at $338K in Q3 2020. 43 funds tracked by Wall St. Rank hold RDHL as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Redhill Biopharma position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 43 Redhill Biopharma shares in Q1 2022, an estimated $110K.
  • Parametric Portfolio Associates first reported a position in Redhill Biopharma in Q4 2019 and held it in 9 quarters.
  • Parametric Portfolio Associates's Redhill Biopharma position peaked at $338K in Q3 2020.
  • 43 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.